Ono Announces Results of Tender Offer to Acquire Deciphera Pharmaceuticals and Completion of Acquisition of Deciphera (a Wholly Owned Subsidiary of Ono)

Core Points - Ono Pharmaceutical has successfully completed the tender offer to acquire Deciphera Pharmaceuticals for US$25.60 per share, totaling approximately US$2.4 billion [5][6] - The tender offer period was from May 13, 2024, to June 10, 2024, with 76,413,423 shares, representing 88.25% of Deciphera's outstanding shares, validly tendered [6][11] - Following the acquisition, Deciphera became a wholly-owned subsidiary of Ono, and its shares ceased trading on Nasdaq [11][13] Overview of the Tender Offer - The tender offer was initiated by Topaz Merger Sub, Inc., a wholly owned subsidiary of Ono [2] - The offer price was set at US$25.60 per share, net to the seller in cash [2][5] - The consummation of the tender offer required a majority of Deciphera's outstanding shares to be validly tendered [2][6] Financial Impact of the Acquisition - The acquisition is expected to leverage Deciphera's research and development capabilities in oncology and enhance Ono's global expansion strategy [6] - Deciphera's total assets as of March 31, 2024, were reported at US$473.566 million, with a revenue of US$163.356 million for the fiscal year ended December 31, 2023 [9][15] - Deciphera reported a net loss of US$194.942 million for the fiscal year ended December 31, 2023, with a net loss per share of US$2.29 [9][15]